INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, irreversible, and fatal lung disease, with an estimated median survival time of 2-5 years following diagnosis [1] [2] [3] [4] [5] . Studies conducted throughout Europe have estimated the prevalence of IPF to range between 1-23/ 100,000 persons [6] [7] [8] [9] [10] [11] .
Pirfenidone is an orally active, synthetic small molecule that inhibits the synthesis of transforming growth factor b and tumor necrosis factor-a, both of which have been demonstrated to play an active role in the fibrosis observed in IPF [12] [13] [14] [15] [16] [17] . Pirfenidone (Esbriet Ò , InterMune) was the first treatment for IPF licensed for use in the Europe Union (2011), followed by Canada (2012), and the United States (2014) [18] . Pirfenidone has also been approved for marketing in Norway and Iceland, and is marketed under different trade names in China, India, Japan, South Korea, Argentina, and Mexico [18] . In October 2014, the Food and [20] . Pirfenidone is generally well tolerated, with gastrointestinal and skin-related events being the most common adverse events (AEs). Analyses from pooled clinical trial data demonstrate that the most frequently reported AEs experienced with pirfenidone, versus placebo, were nausea (32% vs. 12%), rash (26% vs. 8%), diarrhea (20% vs. 14%), fatigue (19% vs. 10%), dyspepsia (16% vs. 5%), anorexia (11% vs. 4%), headache (10% vs. 8%), and photosensitivity reactions (9% vs. 1%) [23] . However, these events rarely led to treatment discontinuation during clinical studies [20, 21] .
Critically, these common AEs may first arise at the initiation of pirfenidone therapy, when patients are still adjusting to their condition and treatment plan. Longer term safety findings from a study in which patients received pirfenidone for a median duration of 2.6 years (2,059 person exposure years) are consistent with the short-term observations [24] .
Recommendations for managing, or even preventing, common AEs have been developed by a panel of experts in pulmonology, gastroenterology, and dermatology [25] . Gastrointestinal events can be addressed by simple measures such as taking pirfenidone with food (preferably at the end of a meal, or in split doses throughout a meal), or in some cases temporary dose reduction/interruption with slow re-escalation to the recommended dose [25, 26] . Skin-related AEs can be prevented and/or managed primarily by patient behavioral modification, such as avoiding exposure to intense sunlight, frequently applying a broad spectrum, high-protection sunscreen, and using protective clothing (wide-brimmed hat, sunglasses, long-sleeve shirt, trousers, gloves) when outdoors or driving [25] .
As with other chronic and progressive diseases, treatment adherence (defined as the extent to which a patient acts in accordance with the prescribed dose and interval of a treatment regime [27] ), is of vital importance for patients to experience maximum benefit. Real-world management of adherence and patient expectation can be variable (from clinician to clinician and from patient to patient) compared with standardized clinical trials, and thus may present particular challenges for patients with IPF receiving pirfenidone. For example, patients may face difficulties in understanding and accepting this unfamiliar, chronic, irreversible disease [28] .
Patients may also struggle with understanding the importance of adhering to the guidance and management plan advised by their physicians, particularly with regard to titrating their dose (following treatment initiation, pirfenidone is titrated over a 14-day The first call from the nurse is lightly scripted: the nurse will ask patients how they are coping with their condition and with treatment. The nurse will take the opportunity during this initial contact to ensure that the patients have understood the instructions from the physician regarding how and when to take their pirfenidone dose, and how to up-titrate during the first few weeks. There will also be discussion with the patient regarding any treatment-related AEs they may be experiencing, and guidance is provided by the nurse on how the patient can prevent and/or self-manage these AEs.
Following the initial call, there is a follow-up call every week or every fortnight for the first month. Once the patient is established on therapy, the timing and frequency of subsequent calls are decided upon by the nurse and patient together, depending on how many calls the patient feels he/she would need (or like) to receive, and how much support and education the nurse feels is required to help the individual patient adhere to the treatment plan, explain that all these topics will be discussed in greater detail during the initial face-to-face meeting, and will ask the patient if there are any other specific topics that they would like to cover at the meeting, so that adequate preparation can be made.
The initial face-to-face meeting usually lasts between 1 and 2 h, and ideally occurs before the patient has initiated pirfenidone treatment [or as early as possible after treatment initiation (within 1-2 weeks)]. In this way, the patients receive the support and encouragement of the program from the very beginning of their pirfenidone experience. This initial meeting with the patient allows the nurse to assess a number of important points, including: (1) that the patient has received adequate information from the treating physician to understand IPF as a disease, and how it will potentially affect their life, and (2) that the patient is aware of how and when to take pirfenidone, and how to up-titrate the doses during the first few weeks. The nurse will also take the opportunity during this initial face-to-face contact to educate the patient on the additional measures that can be adopted to prevent or manage the gastrointestinal and skin-related AEs (such as splitting the dose, taking doses during or at the end of a meal, and using additional sun protection), and to emphasize the importance of adhering to these measures so that they can persist with therapy and experience the maximum benefit of pirfenidone treatment. The patients will also be made aware of any additional sources of information and support that may be available IPF Care provides flexibility with regard to the duration of these conversations, as patients continue on therapy. The length of follow-up calls/visits is determined by the patient-nurse interactions. This allows the nurse the opportunity to reinforce AE management and prevention measures and to assess that the patient has understood the information from the treating physician regarding titration.
BENEFITS OF IPF CARE AS OBSERVED IN THE UK AND AUSTRIAN PROGRAMS
Similarly, the patient has the opportunity to highlight topics they would like explained or discussed in greater detail. As all follow-up calls in IPF Care are patient-led, every call is individualized.
Patients have different experiences and outlooks, as they continue to live with and manage this chronic condition. (Table 1) , and the frequency with which these topics were discussed during the calls was calculated. includes patients who are starting titration again, after a break in treatment or following intolerance to the full dose. Titrating new: includes patients who are continuing with their first titration attempt 
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The most frequently discussed topics (total mentions, all calls) during these conversations were not directly related to pirfenidone treatment (Fig. 2a) . Patients were more likely to talk about test results (lung function tests, chest X-rays, and echocardiograms), oxygen and homecare/drug delivery (Fig. 2b) . Other illnesses and associated treatments were also frequently discussed during the calls (Table 1) . (Fig. 3) . The first call will usually take place while the patients are up-titrating their dose over a setting, which report that gastrointestinal and skin-related AEs tend to occur within the first 6 months of treatment and decrease in frequency over time [24] .
When analyzed by number of patients, 140/239 patients (59%) reported at least one AE during these calls. Of these 140 patients who reported at least one AE, the majority (66%) remained on maintenance therapy, with a smaller proportion (13%) discontinuing treatment (Fig. 4) .
Patient-Reported Satisfaction with the Program was High
Over the past 20 years, patient satisfaction surveys have gained increasing acceptance as sources of information for assessing and improving healthcare resources [29] . Research indicates that better 'patient care experiences' are associated with higher levels of adherence to prevention and treatment interventions, better clinical outcomes, better patient safety within hospitals, and less healthcare utilization [30] . A survey assessing patient satisfaction in IPF Care was performed to ascertain how patients feel about the program with regard to disease management and education. Patients diagnosed with IPF in the previous 12 months, who were participating in IPF Care for longer than 4 weeks and who were on maintenance Table 2) .
The majority of patients also reported that the topics discussed with the specialist nurses were 'the same' or 'similar' to the topics discussed at clinic visits (Fig. 6) . However, general feedback suggested that patients were more comfortable and relaxed discussing these topics over the It should be noted that as only patients on maintenance therapy were chosen to participate in the survey, this may represent a selection bias. These patients were tolerating the full dose of pirfenidone with little or no AEs, and may therefore not have received as many calls from the IPF Care nurse as patients struggling with tolerating the full pirfenidone dose.
FINDINGS FROM IPF CARE IN AUSTRIA
At time of writing, there are currently 69 patients in IPF Care in Austria, which is 
PLACING OUR OBSERVATIONS IN CONTEXT: FINDINGS FROM OTHER PATIENT SUPPORT PROGRAMS
To place our observations in context, and to support the value of patient education and empowerment in improving treatment adherence and patient outcomes, we reviewed previous publications on patient support programs, both in IPF and in other chronic diseases. A small, pirfenidone access program (operating on the basis of named patient supply) served as a precursor to IPF Care in the UK [31] . In this real-world analysis of 40 patients with IPF, six patients (15%) (that imparted self-management principles, and provided telephonic nursing outreach and an action plan for symptom exacerbation) were compared with data from the same number of patients who accessed care from their physician or through emergency departments (control group) [33] . At 1 year, physician visits were significantly less frequent for patients in the program compared with the control group. Hospital admission, bed days and emergency Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
